drugset / Trial / NCT01238991
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Phase 2
Terminated
53 enrolled
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in the preceding P2 double blind studies.
Timeline
- Start
- 2010-12
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vanutide Cridificar | Vaccine | 3 ug | Intramuscular |
| Subject | Vanutide Cridificar | Vaccine | 10 ug | Intramuscular |
| Subject | Vanutide Cridificar | Vaccine | 30 ug | Intramuscular |